Technical Analysis for FATE - Fate Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 16.515 1.01% 0.17
FATE closed down 0.97 percent on Tuesday, January 15, 2019, on 72 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical FATE trend table...

Date Alert Name Type % Chg
Jan 15 Wide Bands Range Expansion 1.01%
Jan 15 Overbought Stochastic Strength 1.01%
Jan 15 Down 3 Days in a Row Weakness 1.01%
Jan 14 Spinning Top Other 0.03%
Jan 14 NR7 Range Contraction 0.03%
Jan 14 NR7-2 Range Contraction 0.03%
Jan 14 Wide Bands Range Expansion 0.03%
Jan 14 Overbought Stochastic Strength 0.03%
Jan 14 Gapped Down Weakness 0.03%
Jan 11 Stochastic Sell Signal Bearish -3.08%

Older signals for FATE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Is FATE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.98
52 Week Low 6.76
Average Volume 893,854
200-Day Moving Average 12.4422
50-Day Moving Average 14.353
20-Day Moving Average 14.3265
10-Day Moving Average 15.999
Average True Range 1.2566
ADX 23.31
+DI 26.4397
-DI 20.1845
Chandelier Exit (Long, 3 ATRs ) 14.0702
Chandelier Exit (Short, 3 ATRs ) 14.7698
Upper Bollinger Band 18.5819
Lower Bollinger Band 10.0711
Percent B (%b) 0.74
BandWidth 59.405996
MACD Line 0.7568
MACD Signal Line 0.4127
MACD Histogram 0.3441
Fundamentals Value
Market Cap 677.12 Million
Num Shares 41.4 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -17.03
Price-to-Sales 42.87
Price-to-Book 3.19
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.75
Resistance 3 (R3) 17.73 17.26 17.51
Resistance 2 (R2) 17.26 16.90 17.26 17.43
Resistance 1 (R1) 16.80 16.68 16.57 16.82 17.36
Pivot Point 16.33 16.33 16.21 16.33 16.33
Support 1 (S1) 15.87 15.97 15.64 15.89 15.34
Support 2 (S2) 15.40 15.75 15.40 15.27
Support 3 (S3) 14.94 15.40 15.19
Support 4 (S4) 14.96